DB
FBIO icon

Dmitry Balyasny’s Fortress Biotech FBIO Stock Holding History

Dmitry Balyasny’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,010
Closed -$13K – 2959
2022
Q2 		$13K Buy
+1,010
New +$15K ﹤0.01% 2545

Other funds holding FBIO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.88B AUM 54.21% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
CL
CPWM LLC Seattle, Washington $1.06B AUM 14.49% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dmitry Balyasny's FBIO Position: Q3 2022 in Review

Dmitry Balyasny sold out of Fortress Biotech (FBIO) in Q3 2022, closing a stake of 1,010 shares — an estimated $13K sold.

Dmitry Balyasny first reported a position in FBIO in Q2 2022 and held it in 1 quarter. The position peaked at $13K in Q2 2022. 64 funds tracked by Wall St. Rank hold FBIO as of Q3 2022.

  • Dmitry Balyasny reported no remaining Fortress Biotech position as of Q3 2022 after selling out during the quarter.
  • Dmitry Balyasny sold 1,010 Fortress Biotech shares in Q3 2022, an estimated $13K.
  • Dmitry Balyasny first reported a position in Fortress Biotech in Q2 2022 and held it in 1 quarter.
  • Dmitry Balyasny's Fortress Biotech position peaked at $13K in Q2 2022.
  • 64 funds tracked by Wall St. Rank held Fortress Biotech as of Q3 2022.

Based on Balyasny Asset Management's 13F filing for Q3 2022, filed 15 Nov 2022.